Switch to:
More From Other Websites
Agios' PK Deficiency Drug AG-348 Gets Orphan Drug Status - Analyst Blog Mar 26 2015
Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog Mar 26 2015
Oncolytics' Cancer Drug Reolysin Gets Orphan Status in EU - Analyst Blog Mar 26 2015
Pfizer & Eli Lilly to Resume Phase III Study of Tanezumab - Analyst Blog Mar 24 2015
Myriad Poised on Portfolio Strength Despite Y/Y Downfall in Q2 - Analyst Blog Mar 23 2015
Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog Mar 23 2015
Eli Lilly Partners with Innovent to Develop Oncology Drugs - Analyst Blog Mar 23 2015
Vertex's Kalydeco Gets FDA Nod for Additional Indication - Analyst Blog Mar 19 2015
Genomic Health Prostrate Cancer Test Grows but Hits Margins - Analyst Blog Mar 18 2015
Is Illumina (ILMN) Worth Adding to Your Portfolio Now? - Analyst Blog Mar 13 2015
Affymetrix Hits 52-Week High on Stellar Q4, Positive Outlook - Analyst Blog Mar 13 2015
XOMA Reports Narrower Y/Y Loss in Q4, Misses on Revs - Analyst Blog Mar 12 2015
Heat Biologics' Bladder Cancer Drug Gets Fast Track Status - Analyst Blog Mar 10 2015
Myriad Genetics Unveils Simoa-based Immunoassay Services - Analyst Blog Mar 09 2015
Forget Gilead Sciences (GILD), Buy These Biotech Stocks Instead - Stocks in the News Mar 06 2015
Shire Submits NDA for Dry Eye Disease Drug Lifitegrast - Analyst Blog Mar 05 2015
Oncolytics' Reolysin Gets Orphan Drug Status Yet Again - Analyst Blog Mar 04 2015
Is Illumina (ILMN) Worth Adding to Your Portfolio Now? - Analyst Blog Mar 03 2015
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog Mar 03 2015
Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog Mar 02 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK